6-K 1 a9212i.htm DIRECTOR/PDMR SHAREHOLDING a9212i
 
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of December 2020
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
 
 
 
 
 
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
Director/PDMR Shareholding
 
 
16 December 2020 18:15 GMT 
 
Transaction by Person Discharging Managerial Responsibilities
Disclosure under Article 19 of the EU Market Abuse Regulation
 
AstraZeneca PLC (the Company) announced that, on 16 December 2020, it was notified of transactions in the Company's Ordinary Shares of $0.25 each  by certain Persons Discharging Managerial Responsibilities (PDMRs) of the Company as set out below.
 
PDMR
Position
Nature of the transaction
Quantity
Price
Philip Broadley
Non-Executive Director
Purchase of Ordinary Shares
1,310
GB£76.25
Nazneen Rahman
Non-Executive Director
Purchase of Ordinary Shares
259
GB£76.78
Nazneen Rahman
Non-Executive Director
Purchase of Ordinary Shares
258
GB£76.79
 
 
 
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
 
1
 
Details of the person discharging managerial responsibilities / person closely associated
 
a)
 
Name
 
 
Philip Broadley
2
 
Reason for the notification
 
a)
 
Position/status
 
 
Non-Executive Director
b)
 
Initial notification /Amendment
 
 
Initial notification
3
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
 
AstraZeneca PLC
b)
 
LEI
 
 
PY6ZZQWO2IZFZC3IOL08
4
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 
 
a)
 
Description of the financial instrument, type of instrument
 
Identification code
 
 
Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 
b)
 
Nature of the transaction
 
 
Purchase of AstraZeneca PLC Ordinary Shares
c)
 
Price(s) and volume(s)
 
 
 
 
 
 
 
Price(s)
 
Volume(s)
 
 
GB£76.25
1,310
 
 
 
 
 
d)
 
Aggregated information
 
 
- Aggregated volume
 
 
- Price
 
 
Not applicable - single transaction
 
e)
 
Date of the transaction
 
 
16 December 2020
f)
 
Place of the transaction
 
 
XLON
 
 
1
 
Details of the person discharging managerial responsibilities / person closely associated
 
a)
 
Name
 
 
Nazneen Rahman
2
 
Reason for the notification
 
a)
 
Position/status
 
 
Non-Executive Director
b)
 
Initial notification /Amendment
 
 
Initial notification
3
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
 
AstraZeneca PLC
b)
 
LEI
 
 
PY6ZZQWO2IZFZC3IOL08
4
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 
 
a)
 
Description of the financial instrument, type of instrument
 
Identification code
 
 
Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 
b)
 
Nature of the transaction
 
 
Purchase of AstraZeneca PLC Ordinary Shares
c)
 
Price(s) and volume(s)
 
 
 
 
 
 
 
Price(s)
 
Volume(s)
 
 
GB£76.776
259
 
 
GB£76.791
258
 
 
 
 
 
d)
 
Aggregated information
 
 
- Aggregated volume
 
 
- Price
 
 
 
 
 
517
 
 
GB£76.784
e)
 
Date of the transaction
 
 
16 December 2020
f)
 
Place of the transaction
 
 
XLON
 
 
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
 
 
Adrian Kemp
Company Secretary
AstraZeneca PLC
  
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
 
Date: 16 December 2020
 
 
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary